Source: Reuters
“The U.S. FDA has approved Freenome’s blood-based colorectal cancer screening test for older adults, paving the way for partner Abbott to launch it in the U.S. this fall, the companies said on Monday.
Shares of Freenome were up about 4% in morning trading. … The test, SimpleScreen CRC, detects signals linked to colorectal cancer from DNA fragments circulating in the blood. Abbott is likely to market SimpleScreen to people who do not complete or decline stool-based screening tests, Brennan said.” (07/27/26)